Circulating Fibroinflammatory Proteins in Liver Remodeling: Mechanisms, Clinical Implications, and Emerging Therapeutics

Abstract

Liver remodeling is a dynamic process orchestrated by complex interactions among parenchymal and non-parenchymal cells, extracellular matrix (ECM) components, and various circulating fibroinflammatory proteins. These proteins play pivotal roles in hepatic repair, fibrosis, and the progression or resolution of chronic liver diseases. This review synthesizes current evidence on the mechanistic roles, clinical significance, and diagnostic utility of circulating fibroinflammatory proteins in liver remodeling, emphasizing their potential as biomarkers and therapeutic targets. We discuss epidemiological trends, pathophysiological mechanisms, risk factors, clinical features, diagnostic approaches, current and emerging treatment strategies, as well as established guideline recommendations, providing a comprehensive resource for clinicians and researchers engaged in hepatology.

Introduction

Liver diseases, including chronic hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and cirrhosis, impose a significant global health burden. Liver remodeling, a process involving both injury-induced fibrogenesis and reparative mechanisms, determines clinical outcomes in these disorders. Fibroinflammatory proteins, such as transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and various cytokines, have emerged as key mediators in the orchestration of hepatic remodeling. Understanding their roles in disease progression, diagnosis, and management is crucial for advancing patient care and developing novel therapeutic interventions.

Epidemiology / Disease Burden

Chronic liver disease affects over 1.5 billion individuals worldwide, with liver fibrosis and cirrhosis accounting for substantial morbidity and mortality. NAFLD is now the most common liver disorder globally, paralleling the rise in obesity and metabolic syndrome. The burden of fibroinflammatory remodeling is evident in populations with chronic hepatitis B and C, where persistent inflammation and fibrosis drive progression to end-stage liver disease. Epidemiological studies highlight significant geographical and demographic variations, with higher prevalence and worse outcomes observed in low- and middle-income countries due to delayed diagnosis and limited access to advanced therapies. Understanding the circulating markers of fibroinflammation offers promise for early detection and improved prognostication in these populations.

Pathophysiology

Liver remodeling is initiated by hepatocellular injury from diverse etiologies, triggering the activation of Kupffer cells, hepatic stellate cells (HSCs), and portal fibroblasts. Fibroinflammatory proteins act as signaling mediators, modulating the balance between ECM deposition and degradation. TGF-β, a master regulator, stimulates HSC transformation into myofibroblasts, enhancing collagen production and fibrogenesis. Pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), perpetuate immune cell recruitment and amplify tissue injury. Conversely, MMPs promote ECM degradation, while TIMPs counteract their activity, collectively determining the net remodeling response. Dysregulation of these proteins leads to excessive fibrosis, architectural distortion, and impaired hepatic function.

Risk Factors

Risk factors for pathological liver remodeling include chronic viral hepatitis (HBV, HCV), sustained alcohol consumption, metabolic syndrome, obesity, type 2 diabetes, and genetic predispositions such as PNPLA3 and TM6SF2 polymorphisms. Environmental toxins, certain medications, and autoimmune conditions also contribute. Persistent hepatic injury and unresolved inflammation drive the chronic release of fibroinflammatory proteins, predisposing individuals to progressive fibrosis and cirrhosis. Host factors influencing immune response and ECM turnover further modulate the risk and rate of disease progression.

Clinical Features

The clinical manifestations of liver remodeling are often insidious, with early stages being asymptomatic. As fibrosis progresses, patients may develop hepatomegaly, splenomegaly, and biochemical abnormalities such as elevated transaminases and markers of cholestasis. Advanced disease presents with features of portal hypertension (ascites, variceal bleeding), hepatic encephalopathy, and coagulopathy. The presence and levels of circulating fibroinflammatory proteins have been correlated with disease severity and outcomes, underscoring their potential as non-invasive biomarkers for staging and prognostication.

Diagnosis

Diagnosis of liver remodeling traditionally relies on clinical assessment, laboratory evaluation, imaging modalities (ultrasound, transient elastography, MRI), and histopathology from liver biopsy. In recent years, quantification of circulating fibroinflammatory proteins—including TGF-β, CTGF, MMPs, TIMPs, and selected cytokines—has gained traction as a non-invasive diagnostic adjunct. Multiplex assays allow simultaneous measurement of multiple markers, enhancing sensitivity and specificity for detecting significant fibrosis and predicting clinical outcomes. Integration of these biomarkers into existing algorithms (e.g., FibroTest, ELF score) is being validated in clinical practice, offering practical advantages in risk stratification and longitudinal monitoring.

Treatment & Management

Management of pathological liver remodeling centers on addressing the underlying etiology—antiviral therapy for viral hepatitis, alcohol cessation, metabolic control for NAFLD, and immunosuppression for autoimmune hepatitis. Anti-fibrotic strategies focus on modulating fibroinflammatory signaling pathways. Agents targeting TGF-β signaling, MMP activity, and cytokine cascades are in various stages of preclinical and clinical development. Supportive care includes management of complications, nutritional support, and consideration of liver transplantation in end-stage disease. Early identification of patients at risk for progressive fibrosis, guided by circulating protein biomarkers, enables timely intervention and improved clinical outcomes.

Recent Advances / Emerging Therapies

Recent advances in molecular profiling and high-throughput proteomics have elucidated novel fibroinflammatory proteins implicated in liver remodeling, such as galectin-3, osteopontin, and periostin. These proteins are being explored as therapeutic targets and prognostic markers. Monoclonal antibodies, small molecule inhibitors, and RNA-based therapies directed at TGF-β, CTGF, and associated pathways show promise in preclinical models and early-phase clinical trials. Precision medicine approaches, integrating proteomic signatures with genetic and clinical data, are refining patient selection and response prediction for anti-fibrotic therapies. Furthermore, liquid biopsy techniques using circulating fibroinflammatory proteins are enhancing non-invasive disease monitoring and facilitating adaptive treatment strategies.

Guideline Recommendations

Major hepatology societies, including AASLD, EASL, and APASL, endorse the use of non-invasive markers—including select fibroinflammatory proteins—for fibrosis assessment in chronic liver disease. Guidelines emphasize comprehensive risk factor modification, etiological treatment, and regular surveillance for disease progression and complications. Although no anti-fibrotic therapy is currently standard of care, integration of emerging protein biomarkers into diagnostic and management pathways is increasingly advocated to personalize care and optimize patient outcomes.

Conclusion

Circulating fibroinflammatory proteins are central mediators of liver remodeling, offering significant promise as diagnostic and prognostic biomarkers and as targets for novel therapies. Advances in proteomics and molecular medicine are accelerating the translation of these proteins from bench to bedside, with the potential to transform the paradigm of liver disease management. Ongoing research and clinical trials will further clarify their utility in guiding therapeutic decisions, monitoring treatment response, and improving long-term outcomes for patients with chronic liver disease.